Editorial response: Discordance between virological, immunologic, and clinical outcomes of therapy with protease inhibitors among human immunodeficiency virus-infected patients

被引：6

作者：

Goetz, MB

机构：

[1] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA

[2] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA

来源：

CLINICAL INFECTIOUS DISEASES | 1999年 / 29卷 / 06期

关键词：

D O I：

10.1086/313563

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1431 / 1434

页数：4

共 46 条

[1] An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses [J].

André, P ;

Groettrup, M ;

Klenerman, P ;

de Giuli, R ;

Booth, BL ;

Cerundolo, V ;

Bonneville, M ;

Jotereau, F ;

Zinkernagel, RM ;

Lotteau, V .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13120-13124

[2] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].

Autran, B ;

Carcelain, G ;

Li, TS ;

Blanc, C ;

Mathez, D ;

Tubiana, R ;

Katlama, C ;

Debre, P ;

Leibowitch, J .

SCIENCE, 1997, 277 (5322) :112-116

[3] Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].

Carpenter, CCJ ;

Fischl, MA ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schooley, RT ;

Thompson, MA ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86

[4] HLA and HIV-1:: Heterozygote advantage and B*35-Cw*04 disadvantage [J].

Carrington, M ;

Nelson, GW ;

Martin, MP ;

Kissner, T ;

Vlahov, D ;

Goedert, JJ ;

Kaslow, R ;

Buchbinder, S ;

Hoots, K ;

O'Brien, SJ .

SCIENCE, 1999, 283 (5408) :1748-1752

[5] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].

COFFIN, JM .

SCIENCE, 1995, 267 (5197) :483-489

[6]

Cooper D, 1999, LANCET, V353, P2061, DOI 10.1016/S0140-6736(98)10391-4

[7] Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J].

Dean, M ;

Carrington, M ;

Winkler, C ;

Huttley, GA ;

Smith, MW ;

Allikmets, R ;

Goedert, JJ ;

Buchbinder, SP ;

Vittinghoff, E ;

Gomperts, E ;

Donfield, S ;

Vlahov, D ;

Kaslow, R ;

Saah, A ;

Rinaldo, C ;

Detels, R ;

OBrien, SJ .

SCIENCE, 1996, 273 (5283) :1856-1862

[8]

DEEKS S, 1999, 6 C RETR OPP INF CHI

[9] HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy [J].

Deeks, SG ;

Hecht, FM ;

Swanson, M ;

Elbeik, T ;

Loftus, R ;

Cohen, PT ;

Grant, RM .

AIDS, 1999, 13 (06) :F35-F43

[10] Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].

Durant, J ;

Clevenbergh, P ;

Halfon, P ;

Delgiudice, P ;

Porsin, S ;

Simonet, P ;

Montagne, N ;

Boucher, CAB ;

Schapiro, JM ;

Dellamonica, P .

LANCET, 1999, 353 (9171) :2195-2199

← 1 2 3 4 5 →